The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Braftovi (encorafenib) plus Erbitux (cetuximab; EC) and FOLFIRI (folinic acid, fluorouracil and irinotecan) confirmed important goal response fee (ORR) advantages versus the...
